SHANGHAI -- Chinese drugmaker CanSino Biologics is accelerating clinical trials for its coronavirus vaccine even as earnings remained in the red.
Pharmaceuticals
COVID-19 vaccine developer CanSino reports $15m net loss
Chinese company earned no revenue as it has yet to commercialize any products
CanSino Biologics' "Ad5-nCoV" vaccine is undergoing late-stage clinical trial in Russia, Chinese state media reported. © Reuters
Read Next
Latest on Pharmaceuticals
